Balcinrenone/dapagliflozin for heart failure (BalanceD-HF)

Balcinrenone is a novel MR modulator added to dapagliflozin SoC in HFrEF/HFpEF with CKD. Beating active SGLT2i comparator on a hard composite is a high bar; prior MRA (FINEARTS, FIDELIO) showed benefit but add-on effect over SGLT2i is uncertain. Event-driven trial still recruiting with primary completion late 2027; execution and effect-size risk meaningful. Phase 2 (MIRACLE) data modest. Base rate for add-on HF Ph3 success ~40-45%.

The event-driven, randomized, double-blind Phase 3 design and high-risk HF/renal population support event accrual. However, superiority over active dapagliflozin on a cardiovascular composite is demanding, and no supportive prior efficacy data are provided. The non-hospitalized HF component may improve power but adds adjudication risk.

Large, blinded, event-driven Phase 3 in a high-event-rate HF/CKD population gives a credible readout and the composite is clinically relevant. However, superiority is against active dapagliflozin on background standard care, so incremental benefit must be material; no prior efficacy signal is provided, limiting conviction.

Phase 3, randomized double-blind active-controlled design supports reliable inference. The high-risk population with recent HF events and impaired kidney function should generate events, while adding balcinrenone to dapagliflozin has a biologically plausible incremental benefit on HF outcomes. However, the composite includes CV death and multiple HF events, and no prior efficacy data or operational results are provided.

Phase 3 event-driven superiority trial of combo vs established dapagliflozin monotherapy; high-risk post-event HF+CKD population with standard CV/HF composite endpoint; double-blind active-controlled design is sound but no prior Phase 2 efficacy data provided and additive benefit over SGLT2i uncertain; long timeline to 2027 increases execution/disclosure risk.

BalanceD-HF compares balcinrenone (an MRA) + dapagliflozin vs dapagliflozin alone in 4,800 MRA-naïve HF patients. MRAs are proven to reduce HF events. While the phase 2b MIRACLE trial missed a surrogate endpoint due to early termination, the MIRO-CKD trial confirmed safety and target engagement. Adding an MRA here has a very high probability of clinical success.

Phase‑3, double‑blind, active‑controlled trial testing balcinrenone added to dapagliflozin in chronic HF with CKD. Dapagliflozin already reduces CV death/HF events; balcinrenone could further improve outcomes but adds mechanistic uncertainty. Large multinational enrollment and event‑driven design increase power, yet the study is still recruiting, so a modest advantage is plausible. Intrinsic chance of a positive composite ≈57%.

Active comparator trial vs dapagliflozin (proven SGLT2i with strong CV/HF data from DAPA-HF/DELIVER) sets a very high bar. Adding balcinrenone on top must show incremental benefit in HF with impaired kidney function—a harder-to-treat population where MR-targeting agents face hyperkalemia risk. Composite includes softer 'HF event without hospitalization' which aids powering but dilutes clinical rigor. Trial still recruiting with ~451 days to primary completion, adding operational risk. No interim efficacy disclosed. Sponsor (AZN) has strong CV trial expertise, but superiority over an...